Neoplastic stem cells: a novel therapeutic target in clinical oncology
- PMID: 17039500
- DOI: 10.1002/cncr.22277
Neoplastic stem cells: a novel therapeutic target in clinical oncology
Abstract
Cancer is among the leading causes of morbidity and mortality in the Western world. Despite recent advances, most therapeutic approaches fail to eradicate the entire neoplastic clone. The remaining cells often develop metastasis and/or recurrences and therefore may represent attractive targets of therapy. A new exciting concept in this regard suggests that each neoplasm represents a heterogeneous population of cells that pertain to long-term tumor growth both in vivo in the natural host and in experimental animals. This concept postulates the existence of small fractions of 'tumor stem cells' that exhibit a capacity for self-renewal and unlimited growth and therefore are distinct from their progeny. Based on these hypotheses, the targeting of neoplastic stem cells is considered indispensable for eradication of the entire clone and for the development of curative treatment approaches. However, tumor stem cells often may be quiescent cells and may express a different profile of targets compared with 'more mature' tumor cells. Therefore, current efforts have attempted to characterize target expression profiles in cancer stem cells in various malignancies. In the this review, the authors have provided a brief summary of the current knowledge of neoplastic stem cells and the application of respective concepts in translational oncology with the ultimate objective of improving anticancer therapy.
Similar articles
-
New hope for cancer treatment: exploring the distinction between normal adult stem cells and cancer stem cells.Pharmacol Ther. 2008 Jul;119(1):74-82. doi: 10.1016/j.pharmthera.2008.04.008. Epub 2008 May 20. Pharmacol Ther. 2008. PMID: 18562010 Review.
-
Neoplastic stem cells: current concepts and clinical perspectives.Crit Rev Oncol Hematol. 2010 Nov;76(2):79-98. doi: 10.1016/j.critrevonc.2010.01.001. Epub 2010 Feb 25. Crit Rev Oncol Hematol. 2010. PMID: 20185329 Review.
-
Cancer stem cells and oncology therapeutics.Curr Opin Oncol. 2007 Jan;19(1):61-4. doi: 10.1097/CCO.0b013e328011a8d6. Curr Opin Oncol. 2007. PMID: 17133114 Review.
-
Human leukaemic stem cells: a novel target of therapy.Eur J Clin Invest. 2004 Aug;34 Suppl 2:31-40. doi: 10.1111/j.0960-135X.2004.01368.x. Eur J Clin Invest. 2004. PMID: 15291804 Review.
-
Cancer stem cells: a review.ANZ J Surg. 2007 Jun;77(6):464-8. doi: 10.1111/j.1445-2197.2007.04096.x. ANZ J Surg. 2007. PMID: 17501888 Review.
Cited by
-
Neuroblastoma cells negative for CD44 possess tumor-initiating properties.Cell Oncol (Dordr). 2011 Jun;34(3):189-97. doi: 10.1007/s13402-011-0022-z. Epub 2011 Mar 22. Cell Oncol (Dordr). 2011. PMID: 21424816
-
Comparison of mammosphere formation from breast cancer cell lines and primary breast tumors.J Thorac Dis. 2014 Jun;6(6):829-37. doi: 10.3978/j.issn.2072-1439.2014.03.38. J Thorac Dis. 2014. PMID: 24977009 Free PMC article.
-
Activation of Matrix Hyaluronan-Mediated CD44 Signaling, Epigenetic Regulation and Chemoresistance in Head and Neck Cancer Stem Cells.Int J Mol Sci. 2017 Aug 24;18(9):1849. doi: 10.3390/ijms18091849. Int J Mol Sci. 2017. PMID: 28837080 Free PMC article. Review.
-
Naphthylisoindolinone alkaloids: the first ring-contracted naphthylisoquinolines, from the tropical liana Ancistrocladus abbreviatus, with cytotoxic activity.RSC Adv. 2022 Oct 12;12(45):28916-28928. doi: 10.1039/d2ra05758a. eCollection 2022 Oct 11. RSC Adv. 2022. PMID: 36320727 Free PMC article.
-
Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.Am J Cancer Res. 2015 Jan 15;5(2):560-74. eCollection 2015. Am J Cancer Res. 2015. PMID: 25973297 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources